Sign up today to learn more about Mammoth Biosciences stock

EquityZen is a marketplace for shares of proven pre IPO tech companies

Mammoth Biosciences Stock

CRISPR-Based Disease Detection Platform

Founded

2017

Notable Investors

Mayfield Fund

Headquarters

San Francisco CA, US

Total Funding

$112M

About Mammoth Biosciences Stock

Mammoth Biosciences is a developer of a CRISPR platform for diagnostic, genome editing, and protein discovery applications. Mammoth's Diagnostic services allows customers to detect molecules that may be indicative of a particular disease. Genome editing services allows customers to edit DNA sequences. Mammoth's protein discovery segment aims to expand CRISPR applications by detecting new proteins that fit CRISPR requirements.

Mammoth Biosciences was founded in 2017 and based in San Francisco, California.

Investors

Funding History

July 2018$18.1M
January 2020$36.8M
January 2020$7.4M
May 2020$49.3M
May 2020$748K

Management

Chief Executive Officer

Trevor Martin

Chief Technology Officer

Janice Chen

Chief Science Officer

Lucas Harrington

Press

Other Companies

EquityZen does not have an affiliation with, formal relationship with, or endorsement from Mammoth Biosciences or any companies feature above. This profile is based on publicly available information and is intended to be informative in nature.

Some data provided by Crunchbase

Join 110K+ Investors and Shareholders

On our trusted digital marketplace for private companies

EquityZen Recognized As:

LogoLogo